Pragmatic issues in biomarker evaluation for targeted therapies in cancer
- PMID: 25421275
- DOI: 10.1038/nrclinonc.2014.202
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
Abstract
Predictive biomarkers are becoming increasingly important tools in drug development and clinical research. The importance of using both guidelines for specimen acquisition and analytical methods for biomarker measurements that are standardized has become recognized widely as an important issue, which must be addressed in order to provide high-quality, validated assays. Herein, we review the major challenges in biomarker validation processes, including pre-analytical (sample-related), analytical, and post-analytical (data-related) aspects of assay development. Recommendations for improving biomarker assay development and method validation are proposed to facilitate the use of predictive biomarkers in clinical trials and the practice of oncology.
Similar articles
-
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016. J Immunother Cancer. 2016. PMID: 27891226 Free PMC article. Review.
-
Validation of analytic methods for biomarkers used in drug development.Clin Cancer Res. 2008 Oct 1;14(19):5967-76. doi: 10.1158/1078-0432.CCR-07-4535. Clin Cancer Res. 2008. PMID: 18829475 Free PMC article. Review.
-
Theory and practice of clinical pharmacodynamics in oncology drug development.Semin Oncol. 2016 Aug;43(4):427-35. doi: 10.1053/j.seminoncol.2016.07.001. Epub 2016 Jul 26. Semin Oncol. 2016. PMID: 27663474
-
[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Z Evid Fortbild Qual Gesundhwes. 2012. PMID: 22325103 Review. German.
-
Targeted Cancer Therapies World Congress 2010--part 2. 21-23 September 2010, Zurich, Switzerland.IDrugs. 2010 Dec;13(12):833-5. IDrugs. 2010. PMID: 21154137
Cited by
-
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr. PLoS Comput Biol. 2016. PMID: 27035903 Free PMC article.
-
Stem Cell Extracellular Vesicles: Extended Messages of Regeneration.Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:125-154. doi: 10.1146/annurev-pharmtox-061616-030146. Epub 2016 Oct 28. Annu Rev Pharmacol Toxicol. 2017. PMID: 27814025 Free PMC article. Review.
-
MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas.J Clin Med. 2015 Aug 18;4(8):1631-50. doi: 10.3390/jcm4081631. J Clin Med. 2015. PMID: 26295264 Free PMC article. Review.
-
Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Genomics Proteomics Bioinformatics. 2017 Aug;15(4):220-235. doi: 10.1016/j.gpb.2016.11.005. Epub 2017 Aug 13. Genomics Proteomics Bioinformatics. 2017. PMID: 28813639 Free PMC article. Review.
-
Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.J Natl Cancer Inst. 2015 Nov 20;108(4):djv351. doi: 10.1093/jnci/djv351. Print 2016 Apr. J Natl Cancer Inst. 2015. PMID: 26590952 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources